|
US20130266551A1
(en)
*
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
AU2012242847B2
(en)
|
2011-04-15 |
2017-01-19 |
The Johns Hopkins University |
Safe sequencing system
|
|
KR20140127816A
(ko)
|
2012-02-22 |
2014-11-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
|
|
EP2912468B1
(en)
|
2012-10-29 |
2018-09-12 |
The Johns Hopkins University |
Papanicolaou test for ovarian and endometrial cancers
|
|
WO2014100615A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
CN111139256A
(zh)
|
2013-02-20 |
2020-05-12 |
诺华股份有限公司 |
使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP4420663A3
(en)
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
AU2014368383B2
(en)
|
2013-12-20 |
2020-01-16 |
Cellectis |
Method of engineering multi-input signal sensitive T cell for immunotherapy
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
US10189908B2
(en)
|
2014-02-05 |
2019-01-29 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
|
|
WO2015120363A1
(en)
|
2014-02-10 |
2015-08-13 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
MX370272B
(es)
|
2014-03-19 |
2019-12-09 |
Cellectis |
Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
|
|
LT3129470T
(lt)
|
2014-04-07 |
2021-07-12 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
|
US10611837B2
(en)
|
2014-04-10 |
2020-04-07 |
Seattle Children's Hospital |
Transgene genetic tags and methods of use
|
|
JP2017514522A
(ja)
|
2014-05-02 |
2017-06-08 |
エモリー ユニバーシティー |
ヒト化可変性リンパ球受容体(vlr)および組成物ならびにそれに関連する使用
|
|
AU2015259877B2
(en)
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
EP3149044B1
(en)
|
2014-06-02 |
2020-10-21 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting cd-19
|
|
MX2017000646A
(es)
|
2014-07-15 |
2017-04-27 |
Juno Therapeutics Inc |
Celulas geneticamente modificadas para terapia celular adoptiva.
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll-1嵌合抗原受体的癌症治疗
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
KR102523934B1
(ko)
|
2014-07-24 |
2023-04-20 |
2세븐티 바이오, 인코포레이티드 |
Bcma 키메릭 항원 수용체
|
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
AU2015305531B2
(en)
|
2014-08-19 |
2021-05-20 |
Novartis Ag |
Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
JP2017531430A
(ja)
*
|
2014-10-07 |
2017-10-26 |
セレクティスCellectis |
Carによって誘導される免疫細胞の活性を調節するための方法
|
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
WO2016061368A1
(en)
*
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
MX392487B
(es)
|
2014-10-20 |
2025-03-21 |
Juno Therapeutics Inc |
Métodos y composiciones para dosificación en terapia celular adoptiva.
|
|
BR112017008710A8
(pt)
*
|
2014-10-27 |
2023-04-25 |
Hutchinson Fred Cancer Res |
Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
|
|
WO2016073602A2
(en)
*
|
2014-11-05 |
2016-05-12 |
Juno Therapeutics, Inc. |
Methods for transduction and cell processing
|
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
KR102804498B1
(ko)
|
2014-12-03 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 방법 및 조성물
|
|
CA2970466A1
(en)
|
2014-12-12 |
2016-06-16 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
WO2016097231A2
(en)
*
|
2014-12-17 |
2016-06-23 |
Cellectis |
INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
|
|
CA2972597A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US11382963B2
(en)
|
2015-01-12 |
2022-07-12 |
Pieris Pharmaceuticals Gmbh |
Engineered T cells and uses therefor
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
GB201501004D0
(en)
|
2015-01-21 |
2015-03-04 |
Cancer Rec Tech Ltd |
Inhibitors
|
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
|
AU2016212158B2
(en)
|
2015-01-26 |
2021-06-03 |
Allogene Therapeutics, Inc. |
mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
|
|
EP3250611B1
(en)
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
|
ES3007649T3
(en)
*
|
2015-01-29 |
2025-03-20 |
Univ Minnesota |
Chimeric antigen receptors, compositions, and methods
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US10722523B2
(en)
|
2015-03-17 |
2020-07-28 |
The Regents Of The University Of California |
Chemoimmunotherapy for epithelial cancer
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
HRP20220893T1
(hr)
*
|
2015-04-08 |
2022-10-14 |
Novartis Ag |
Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
|
|
EP3283619B1
(en)
|
2015-04-17 |
2023-04-05 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507368D0
(en)
*
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
HK1250569A1
(zh)
|
2015-05-01 |
2018-12-28 |
The Regents Of The University Of California |
聚醣依赖性免疫治疗分子
|
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
KR20190080992A
(ko)
|
2015-05-21 |
2019-07-08 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
|
US20180161369A1
(en)
|
2015-05-29 |
2018-06-14 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
|
CN108603170A
(zh)
|
2015-06-12 |
2018-09-28 |
莱蒂恩技术公司 |
用工程改造的t细胞治疗癌症的方法
|
|
CN115925971A
(zh)
|
2015-06-19 |
2023-04-07 |
塞巴斯蒂安·科博尔德 |
Pd-1-cd28融合蛋白及其在医学中的用途
|
|
MA42902A
(fr)
*
|
2015-07-08 |
2018-05-16 |
Univ Johns Hopkins |
Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
WO2017009842A2
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
WO2017015783A1
(en)
*
|
2015-07-24 |
2017-02-02 |
Shanghai Sidansai Biotechnology Co., Ltd |
Humanized anti-cd19 antibody and use thereof
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US11458167B2
(en)
*
|
2015-08-07 |
2022-10-04 |
Seattle Children's Hospital |
Bispecific CAR T-cells for solid tumor targeting
|
|
WO2017027653A1
(en)
|
2015-08-11 |
2017-02-16 |
The Johns Hopkins University |
Assaying ovarian cyst fluid
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
WO2017027843A1
(en)
|
2015-08-12 |
2017-02-16 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
|
CN106467906B
(zh)
*
|
2015-08-20 |
2019-09-27 |
北京马力喏生物科技有限公司 |
构建体、转基因淋巴细胞及其制备方法和用途
|
|
US20180243340A1
(en)
*
|
2015-08-24 |
2018-08-30 |
University Of Houston System |
Combination therapy combining car + t cells with appropriately timed immunodulatory antibodies
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
MA44909A
(fr)
*
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
US10265379B2
(en)
*
|
2015-09-16 |
2019-04-23 |
Annabelle Rodriguez Oquendo |
Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
|
|
KR20180050413A
(ko)
|
2015-09-22 |
2018-05-14 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Hiv 감염을 치료하기 위해 t 세포를 리디렉션시키는 방법
|
|
CA2999037A1
(en)
*
|
2015-09-23 |
2017-03-30 |
Cytoimmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
|
EP3355937A4
(en)
*
|
2015-09-28 |
2019-04-17 |
Regents of the University of Minnesota |
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
|
|
EP3660044A1
(en)
*
|
2015-10-09 |
2020-06-03 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
|
PL3362470T3
(pl)
*
|
2015-10-13 |
2022-02-21 |
City Of Hope |
Chimeryczne receptory antygenowe zawierające domenę chlorotoksyny
|
|
MY196631A
(en)
*
|
2015-10-13 |
2023-04-24 |
Eureka Therapeutics Inc |
Antibody Agents Specific for Human Cd19 and uses Thereof
|
|
WO2017064222A1
(en)
|
2015-10-16 |
2017-04-20 |
Ludwig-Maximilians-Universität München |
Cxcr6-transduced t cells for targeted tumor therapy
|
|
WO2017066583A1
(en)
*
|
2015-10-16 |
2017-04-20 |
University Of Utah Research Foundation |
A nanomaterial complex comprising graphene oxide associated with a therapeutic agent and methods of use
|
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
CN105331585A
(zh)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
|
KR102220275B1
(ko)
|
2015-11-18 |
2021-02-26 |
머크 샤프 앤드 돔 코포레이션 |
Pd1 및/또는 lag3 결합제
|
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
|
EP3383419B1
(en)
*
|
2015-12-03 |
2022-08-03 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
|
EP3384294B1
(en)
|
2015-12-04 |
2021-10-13 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
AU2016362129A1
(en)
|
2015-12-04 |
2018-06-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
CN117025539A
(zh)
|
2015-12-28 |
2023-11-10 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
|
SG11201805451TA
(en)
|
2015-12-30 |
2018-07-30 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
CN105950645A
(zh)
*
|
2016-01-11 |
2016-09-21 |
灏灵赛奥(天津)生物科技有限公司 |
Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
|
|
NZ743983A
(en)
|
2016-01-11 |
2025-08-29 |
Univ Leland Stanford Junior |
Chimeric proteins and methods of regulating gene expression
|
|
EP3901258A1
(en)
|
2016-01-11 |
2021-10-27 |
The Board of Trustees of the Leland Stanford Junior University |
Chimeric proteins and methods of immunotherapy
|
|
CN107034193B
(zh)
*
|
2016-02-03 |
2020-06-05 |
北京马力喏生物科技有限公司 |
治疗b细胞白血病及b细胞淋巴瘤的治疗组合物
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
EP3430549A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
|
MX2018010415A
(es)
|
2016-03-18 |
2018-11-29 |
Hutchinson Fred Cancer Res |
Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
RU2018136877A
(ru)
|
2016-03-22 |
2020-04-22 |
СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) |
Способы раннего вмешательства для профилактики или улучшения состояния токсичности
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
WO2017162797A1
(en)
|
2016-03-23 |
2017-09-28 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Fusion proteins of pd-1 and 4-1bb
|
|
KR20230148844A
(ko)
*
|
2016-03-29 |
2023-10-25 |
유니버시티 오브 써던 캘리포니아 |
암을 표적하는 키메라 항원 수용체
|
|
CN109069537B
(zh)
*
|
2016-04-04 |
2022-04-15 |
亘喜生物科技(上海)有限公司 |
共刺激结构域中具有重复结合基序的car
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
IL262321B2
(en)
|
2016-04-15 |
2024-09-01 |
Novartis Ag |
Preparations and methods for selective protein expression
|
|
US11723962B2
(en)
|
2016-05-04 |
2023-08-15 |
Fred Hutchinson Cancer Center |
Cell-based neoantigen vaccines and uses thereof
|
|
CN105950663B
(zh)
*
|
2016-05-17 |
2019-04-02 |
上海优卡迪生物医药科技有限公司 |
一种靶向cd30的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用
|
|
CN105950664B
(zh)
*
|
2016-05-17 |
2019-03-29 |
上海优卡迪生物医药科技有限公司 |
一种靶向cd123的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用
|
|
CN105969805B
(zh)
*
|
2016-05-17 |
2019-03-29 |
上海优卡迪生物医药科技有限公司 |
一种靶向Mesothelin的复制缺陷性重组慢病毒CAR-T转基因载体及其构建方法和应用
|
|
CN105950662B
(zh)
*
|
2016-05-17 |
2019-04-30 |
上海优卡迪生物医药科技有限公司 |
一种靶向cd22的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
AU2017274733A1
(en)
|
2016-06-03 |
2018-12-20 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
|
JP7519660B2
(ja)
*
|
2016-06-14 |
2024-07-22 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
疾患を処置するための遺伝子改変された細胞、組織、および臓器
|
|
CN107523548A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抗体的t细胞及其用途
|
|
CN114891751A
(zh)
*
|
2016-06-20 |
2022-08-12 |
上海细胞治疗研究院 |
一种高效稳定表达激活型抗体的car-t细胞及其用途
|
|
CN106117366A
(zh)
*
|
2016-06-24 |
2016-11-16 |
安徽未名细胞治疗有限公司 |
一种cd19特异性嵌合抗原受体及其编码基因、应用
|
|
EP3475446A1
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
|
CA3026858A1
(en)
|
2016-06-30 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Improved adoptive t-cell therapy
|
|
CN106178163B
(zh)
*
|
2016-07-01 |
2019-02-01 |
翁炳焕 |
艾滋病生物细胞免疫治疗仪
|
|
CN106267409B
(zh)
*
|
2016-07-01 |
2019-02-01 |
翁炳焕 |
艾滋病生物治疗反应器
|
|
CN107586342A
(zh)
*
|
2016-07-08 |
2018-01-16 |
生命序有限公司 |
重组免疫检查点受体及其应用
|
|
CN107586341A
(zh)
*
|
2016-07-08 |
2018-01-16 |
生命序有限公司 |
重组免疫检查点受体及免疫检查点抑制分子的共表达及应用
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CAR-T CD229 LYMPHOCYTES AND METHODS OF USE
|
|
CN106011174B
(zh)
*
|
2016-07-26 |
2019-12-13 |
天晴干细胞股份有限公司 |
一种通用型慢病毒载体及其制备方法
|
|
SG11201900677SA
(en)
*
|
2016-07-28 |
2019-02-27 |
Novartis Ag |
Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
|
|
US20240018268A1
(en)
|
2016-07-29 |
2024-01-18 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies against anti-cd19 antibodies
|
|
MX2019001469A
(es)
|
2016-08-01 |
2019-10-02 |
Novartis Ag |
Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
|
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CN106350487B
(zh)
*
|
2016-09-13 |
2019-01-25 |
北京多赢时代转化医学研究院 |
联合制备car-nk细胞和car-nkt细胞的方法
|
|
CN106399242B
(zh)
*
|
2016-09-13 |
2019-01-22 |
北京多赢时代转化医学研究院 |
联合制备CAR-Vγ9Vδ2T细胞和CAR-NKT细胞的方法
|
|
US11077178B2
(en)
|
2016-09-21 |
2021-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
|
|
JP2019532672A
(ja)
|
2016-09-28 |
2019-11-14 |
ノバルティス アーゲー |
多孔質膜系巨大分子送達システム
|
|
CN106317228A
(zh)
*
|
2016-09-28 |
2017-01-11 |
李华顺 |
一种嵌合抗原受体分子及其应用
|
|
EP4353319A3
(en)
|
2016-09-28 |
2024-06-05 |
Atossa Therapeutics, Inc. |
Methods of adoptive cell therapy
|
|
US11155832B2
(en)
|
2016-09-30 |
2021-10-26 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into T cells
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
AU2017341047B2
(en)
|
2016-10-07 |
2024-10-10 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
ES2939646T3
(es)
|
2016-10-13 |
2023-04-25 |
Juno Therapeutics Inc |
Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
|
|
CN107988164B
(zh)
|
2016-10-26 |
2020-07-07 |
阿思科力(苏州)生物科技有限公司 |
一种pd-1 car nk-92细胞及其制备方法与应用
|
|
CA3040914A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
|
WO2018085731A2
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
|
EP3534968A4
(en)
|
2016-11-04 |
2020-07-01 |
Bluebird Bio, Inc. |
ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
AU2017366739B2
(en)
|
2016-12-02 |
2023-11-23 |
Angeles Therapeutics, Inc. |
Synthetic immune receptors and methods of use thereof
|
|
EP3548622A1
(en)
|
2016-12-02 |
2019-10-09 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
JP2019536460A
(ja)
|
2016-12-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Car−t細胞の調節方法
|
|
MA46995A
(fr)
|
2016-12-03 |
2019-10-09 |
Acerta Pharma Bv |
Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
|
|
ES2961666T3
(es)
|
2016-12-03 |
2024-03-13 |
Juno Therapeutics Inc |
Métodos para determinar la dosificación de células CAR-T
|
|
CA3045665A1
(en)
|
2016-12-12 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
CN108610420B
(zh)
*
|
2016-12-13 |
2023-09-26 |
科济生物医药(上海)有限公司 |
抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
|
|
CN108250301A
(zh)
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
EP3609536B1
(en)
*
|
2017-01-05 |
2022-03-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
|
|
EP3346001A1
(en)
*
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
JP7382829B2
(ja)
*
|
2017-01-10 |
2023-11-17 |
ザ ジェネラル ホスピタル コーポレイション |
キメラ抗原受容体を発現するt細胞
|
|
JP7429338B2
(ja)
|
2017-01-10 |
2024-02-08 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法および関連方法のエピジェネティック解析
|
|
CN107058390A
(zh)
*
|
2017-01-17 |
2017-08-18 |
上海交通大学医学院附属第九人民医院 |
一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラt細胞受容体タンパク質を用いた癌の治療
|
|
CA3051481A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
|
WO2018151836A1
(en)
|
2017-02-17 |
2018-08-23 |
Fred Hutchinson Cancer Research Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
AU2018224856B2
(en)
|
2017-02-27 |
2025-04-03 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
KR102771581B1
(ko)
|
2017-03-14 |
2025-02-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
극저온 보관 방법
|
|
SG11201907434RA
(en)
|
2017-03-22 |
2019-10-30 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
BR112019019917A2
(pt)
|
2017-03-27 |
2020-04-22 |
Nat Univ Singapore |
receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
|
|
CN107058232B
(zh)
*
|
2017-04-12 |
2018-03-30 |
上海优卡迪生物医药科技有限公司 |
胆固醇转脂酶soat1被抑制的car‑t细胞及其制备方法和应用
|
|
MA54103A
(fr)
|
2017-04-14 |
2021-09-15 |
Juno Therapeutics Inc |
Procédés d'évaluation de la glycosylation de surface cellulaire
|
|
JOP20180042A1
(ar)
*
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
CN108728459B
(zh)
*
|
2017-04-24 |
2023-08-04 |
上海恒润达生生物科技股份有限公司 |
靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200078404A1
(en)
|
2017-05-01 |
2020-03-12 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
WO2018218072A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Compositions and methods for an improved antitumor immune response
|
|
CN108977453A
(zh)
|
2017-06-02 |
2018-12-11 |
阿思科力(苏州)生物科技有限公司 |
一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用
|
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
|
CA3061959A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer
|
|
SG11201912010XA
(en)
*
|
2017-06-12 |
2020-01-30 |
Obsidian Therapeutics Inc |
Pde5 compositions and methods for immunotherapy
|
|
EP3644721A1
(en)
|
2017-06-29 |
2020-05-06 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
|
AU2018292181B2
(en)
|
2017-06-30 |
2025-04-10 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
EP3662055A1
(en)
*
|
2017-08-02 |
2020-06-10 |
Autolus Limited |
Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
|
|
IL319255A
(en)
|
2017-08-07 |
2025-04-01 |
Univ Johns Hopkins |
Methods and materials for cancer assessment and treatment
|
|
CN107383196B
(zh)
*
|
2017-08-30 |
2019-12-17 |
广州百暨基因科技有限公司 |
人源化抗cd19的抗原结合片段
|
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
|
US10501539B2
(en)
*
|
2017-09-15 |
2019-12-10 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
|
CN109517796A
(zh)
|
2017-09-18 |
2019-03-26 |
博雅辑因(北京)生物科技有限公司 |
一种基因编辑t细胞及其用途
|
|
MX2020002901A
(es)
|
2017-09-19 |
2020-07-22 |
Massachusetts Inst Technology |
Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
|
|
WO2019067015A1
(en)
*
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
PL3694529T3
(pl)
|
2017-10-13 |
2024-12-16 |
Harpoon Therapeutics, Inc. |
Trójswoiste białka i sposoby zastosowania
|
|
CA3079407A1
(en)
|
2017-10-18 |
2019-04-25 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
KR20200069358A
(ko)
|
2017-10-25 |
2020-06-16 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
SG11202003879RA
(en)
|
2017-10-30 |
2020-05-28 |
Neuropore Therapies Inc |
Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
|
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
|
DK3703710T3
(da)
*
|
2017-10-31 |
2024-10-14 |
Allogene Therapeutics Inc |
Fremgangsmåder og sammensætninger til dosering af allogene kimær antigenreceptor-t-celler til behandling af refraktært og/eller recidiveret storcellet b-cellelymfom eller refraktært og/eller recidiveret follikulært lymfom
|
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
|
PL3704230T3
(pl)
|
2017-11-01 |
2025-02-24 |
Juno Therapeutics, Inc. |
Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie
|
|
WO2019090003A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
SG11202003427XA
(en)
|
2017-11-06 |
2020-05-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
US12024715B2
(en)
|
2017-11-07 |
2024-07-02 |
Temple University-Of The Commonwealth System Of Higher Education |
Compositions and methods for improved T cells
|
|
WO2019094498A1
(en)
*
|
2017-11-07 |
2019-05-16 |
City Of Hope |
Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car
|
|
US11802163B2
(en)
|
2017-11-10 |
2023-10-31 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting glypican-3 or mesothelin
|
|
AU2018369883A1
(en)
|
2017-11-15 |
2020-05-28 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
|
|
JP7517983B2
(ja)
*
|
2017-11-20 |
2024-07-17 |
ユリウス-マクシミリアン-ウニヴェルシテート・ヴュルツブルク |
非常に低レベルのcd19を発現する骨髄腫細胞を除去するcd19cart細胞
|
|
EP3714042A4
(en)
|
2017-11-22 |
2021-08-04 |
La Jolla Institute for Allergy and Immunology |
USE AND PRODUCTION OF MODIFIED IMMUNE CELLS
|
|
CN109836493A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
SG11202005005YA
(en)
|
2017-11-30 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
KR20200116081A
(ko)
|
2017-12-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포의 투약 및 조절 방법
|
|
AU2018379502B2
(en)
*
|
2017-12-06 |
2025-07-17 |
Abclon Inc. |
Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same, and use thereof
|
|
WO2019113557A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
|
EP3720949A1
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
CN107880128B
(zh)
*
|
2017-12-21 |
2021-03-02 |
常州费洛斯药业科技有限公司 |
一种抗cd19的全人源抗体或抗体片段及其方法和应用
|
|
CN109053899B
(zh)
*
|
2017-12-22 |
2021-11-16 |
湖南远泰生物技术有限公司 |
一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
|
|
MY202687A
(en)
*
|
2017-12-23 |
2024-05-15 |
Uwell Biopharma Inc |
Pharmaceutical chimeric receptor composition and method thereof
|
|
US12491153B2
(en)
|
2018-01-03 |
2025-12-09 |
Qu Biologics Inc. |
Innate targeting of adoptive cellular therapies
|
|
EP3737408A1
(en)
|
2018-01-08 |
2020-11-18 |
Novartis AG |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
US10561686B2
(en)
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
JP2021510540A
(ja)
*
|
2018-01-11 |
2021-04-30 |
イノベイティブ セルラー セラピューティクス インク.Innovative Cellular Therapeutics Inc. |
修飾細胞の増幅およびその応用
|
|
JP7068498B2
(ja)
*
|
2018-01-12 |
2022-05-16 |
クロセル インク. |
二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Car t細胞の使用方法
|
|
CN108017717B
(zh)
*
|
2018-01-24 |
2019-08-16 |
首都医科大学宣武医院 |
一种用于体外高效定向扩增的嵌合抗原受体及其应用
|
|
CN110093359B
(zh)
*
|
2018-01-29 |
2023-10-13 |
华南生物医药研究院 |
含cd3启动子序列和car序列的可分离的核酸及应用
|
|
AU2019215031B2
(en)
|
2018-01-31 |
2025-10-09 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CN111936518A
(zh)
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院(Dba西雅图儿童研究所) |
对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
|
|
SG11202007441TA
(en)
|
2018-02-06 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Closed-system manufacturing process for car-t cells
|
|
AU2019219454A1
(en)
|
2018-02-09 |
2020-08-27 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
US20230183313A1
(en)
*
|
2018-02-11 |
2023-06-15 |
Jiangsu Hengrui Medicine Co., Ltd. |
Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
|
|
US12331114B2
(en)
*
|
2018-02-13 |
2025-06-17 |
Indian Institute Of Technology Bombay |
Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
JP7314161B2
(ja)
|
2018-03-14 |
2023-07-25 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法
|
|
EA202092044A1
(ru)
*
|
2018-03-14 |
2021-03-03 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные рецепторы антигена против cd33 и их применения
|
|
JP7438123B2
(ja)
|
2018-03-14 |
2024-02-26 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
腫瘍特異的T細胞免疫療法用のIL-13受容体α2(IL13Rα2)標的キメラ抗原受容体
|
|
US10751399B2
(en)
*
|
2018-03-20 |
2020-08-25 |
Cho Pharma Usa, Inc. |
Chimeric antigen receptors that bind to SSEA4 and uses thereof
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
WO2019200252A1
(en)
|
2018-04-13 |
2019-10-17 |
The Johns Hopkins University |
Non-invasive detection of response to immunotherapy
|
|
WO2019200250A1
(en)
|
2018-04-13 |
2019-10-17 |
Velculescu Victor E |
Non-invasive detection of response to a targeted therapy
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
KR102892725B1
(ko)
|
2018-05-09 |
2025-12-01 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 넥틴4에 특이적인 항체
|
|
US20210198747A1
(en)
|
2018-05-18 |
2021-07-01 |
The Johns Hopkins University |
Cell-free dna for assessing and/or treating cancer
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
CA3101856A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
|
JP7398396B2
(ja)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Bcmaに対する結合分子及びその使用
|
|
CA3101991A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
KR20190141511A
(ko)
*
|
2018-06-14 |
2019-12-24 |
주식회사 녹십자랩셀 |
신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
|
|
AU2019290230A1
(en)
*
|
2018-06-22 |
2020-12-03 |
The General Hospital Corporation |
Chimeric antigen receptors targeting CD37 and CD19
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
AU2019311077B2
(en)
|
2018-07-23 |
2025-05-29 |
Heidelberg Pharma Research Gmbh |
Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
|
|
CN110819679A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞体内代谢的方法
|
|
JP7538109B2
(ja)
|
2018-08-09 |
2024-08-21 |
ジュノー セラピューティクス インコーポレイテッド |
組み込まれた核酸を評価するための方法
|
|
JP7560882B2
(ja)
|
2018-08-29 |
2024-10-03 |
ナショナル ユニヴァーシティー オブ シンガポール |
遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
|
|
BR112021003416A2
(pt)
*
|
2018-08-30 |
2021-05-18 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr usando proteínas de fusão
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
AU2019328677A1
(en)
|
2018-08-31 |
2021-04-01 |
Invectys SA |
Chimeric antigen receptors against multiple HLA-G isoforms
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
WO2020047452A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
JP7582940B2
(ja)
|
2018-10-31 |
2024-11-13 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞の選択および刺激のための方法ならびにそのための装置
|
|
EP3877054B1
(en)
|
2018-11-06 |
2023-11-01 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
US12263190B2
(en)
|
2018-11-08 |
2025-04-01 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
|
CN113271963A
(zh)
|
2018-11-16 |
2021-08-17 |
朱诺治疗学股份有限公司 |
给予工程化t细胞以治疗b细胞恶性肿瘤的方法
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
JP7232547B2
(ja)
*
|
2018-11-29 |
2023-03-03 |
ジョージアン ルイジアメイ バイオテック カンパニー リミテッド |
CDR1領域に突然変異したヒト化CD19 scFvを有するCAR-T細胞
|
|
BR112021010354A2
(pt)
|
2018-11-30 |
2021-11-03 |
Juno Therapeutics Inc |
Métodos para o tratamento usando terapia celular adotiva
|
|
AU2019387494A1
(en)
|
2018-11-30 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of B cell malignancies in adoptive cell therapy
|
|
CN113412117B
(zh)
|
2018-12-12 |
2025-03-04 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
US20220047636A1
(en)
*
|
2018-12-13 |
2022-02-17 |
The General Hospital Corporation |
Chimeric antigen receptors targeting cd79b and cd19
|
|
US20220016171A1
(en)
|
2018-12-18 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
WO2020146432A1
(en)
*
|
2019-01-07 |
2020-07-16 |
Magenta Therapeutics, Inc. |
Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy
|
|
CN109734813B
(zh)
*
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
WO2020163222A1
(en)
*
|
2019-02-04 |
2020-08-13 |
Promab Biotechnologies, Inc. |
Nucleic acid sequence encoding chimeric antigen receptor and a short hairpin rna sequence for il-6 or a checkpoint inhibitor
|
|
US11760786B2
(en)
|
2019-02-06 |
2023-09-19 |
The Regents Of The University Of Michigan |
Chimeric antigen receptors targeting abnormal glycobiology
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
CN113710705B
(zh)
|
2019-03-05 |
2023-07-21 |
湖南远泰生物技术有限公司 |
具有人源化cd19 scfv的car-t细胞
|
|
SG11202109172TA
(en)
|
2019-03-08 |
2021-09-29 |
Obsidian Therapeutics Inc |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
US20220160771A1
(en)
|
2019-04-10 |
2022-05-26 |
Iulia Diaconu |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
BR112021019669A2
(pt)
|
2019-04-12 |
2021-12-07 |
C4 Therapeutics Inc |
Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EP3972998A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
EP4549555A3
(en)
*
|
2019-05-24 |
2025-07-30 |
City of Hope |
Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
|
|
AU2020287882A1
(en)
|
2019-06-07 |
2022-01-20 |
Juno Therapeutics, Inc. |
Automated T cell culture
|
|
AU2020293230A1
(en)
|
2019-06-12 |
2022-01-27 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
CN112390891B
(zh)
*
|
2019-08-14 |
2022-06-03 |
苏州方德门达新药开发有限公司 |
嵌合抗原受体及其构建方法和应用
|
|
JP2022545467A
(ja)
|
2019-08-22 |
2022-10-27 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法
|
|
JP7723420B2
(ja)
*
|
2019-08-28 |
2025-08-14 |
キングス・カレッジ・ロンドン |
B細胞標的化並列CAR(pCAR)治療的薬剤
|
|
EP4028413A1
(en)
|
2019-09-10 |
2022-07-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
CN114929360A
(zh)
|
2019-10-30 |
2022-08-19 |
朱诺治疗学有限公司 |
细胞选择和/或刺激装置及使用方法
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
AR120563A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quimérico cd19 y cd22 y sus usos
|
|
CN115398231A
(zh)
|
2019-12-06 |
2022-11-25 |
朱诺治疗学股份有限公司 |
与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
|
|
US20230028050A1
(en)
|
2019-12-06 |
2023-01-26 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
CN114867850A
(zh)
|
2019-12-30 |
2022-08-05 |
博雅缉因(北京)生物科技有限公司 |
一种纯化ucart细胞的方法与应用
|
|
JP2023509058A
(ja)
|
2019-12-30 |
2023-03-06 |
博雅▲緝▼因(北京)生物科技有限公司 |
T細胞リンパ腫細胞を標的とするユニバーサルcar-tならびにその調製方法及び使用
|
|
WO2021150919A1
(en)
|
2020-01-23 |
2021-07-29 |
The Children's Medical Center Corporation |
Stroma-free t cell differentiation from human pluripotent stem cells
|
|
IL295297A
(en)
|
2020-02-14 |
2022-10-01 |
Univ Johns Hopkins |
Methods and materials for assessing nucleic acids
|
|
US20230111593A1
(en)
|
2020-02-14 |
2023-04-13 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
EP4110823A1
(en)
|
2020-02-26 |
2023-01-04 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN115175695A
(zh)
|
2020-02-27 |
2022-10-11 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
BR112022017216A2
(pt)
|
2020-02-28 |
2022-10-11 |
Takeda Pharmaceuticals Co |
Método para produzir células exterminadoras naturais a partir de células-tronco pluripotentes
|
|
WO2022074464A2
(en)
|
2020-03-05 |
2022-04-14 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
KR20240096884A
(ko)
|
2020-03-10 |
2024-06-26 |
매사추세츠 인스티튜트 오브 테크놀로지 |
조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CN111484561A
(zh)
*
|
2020-04-07 |
2020-08-04 |
北京荣瑷医学生物科技有限责任公司 |
一种靶向于cd19分子的嵌合抗原受体
|
|
CN111411085A
(zh)
*
|
2020-04-10 |
2020-07-14 |
格源致善(上海)生物科技有限公司 |
一种嵌合抗原受体t细胞及其应用
|
|
US12241086B2
(en)
|
2020-04-15 |
2025-03-04 |
Amgen Inc. |
Process for generating genetically engineered autologous T cells
|
|
JP7626780B2
(ja)
*
|
2020-04-15 |
2025-02-04 |
アムジエン・インコーポレーテツド |
遺伝子改変自己t細胞を製造するためのプロセス
|
|
US12378521B2
(en)
|
2020-04-15 |
2025-08-05 |
Amgen Inc. |
Method for enhancing production of genetically engineered autologous T cells
|
|
US20230165872A1
(en)
|
2020-04-28 |
2023-06-01 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
JP2023526278A
(ja)
|
2020-05-13 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
|
|
KR20230024283A
(ko)
|
2020-05-13 |
2023-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
CN111733186A
(zh)
*
|
2020-07-03 |
2020-10-02 |
天津英科赛奥科技有限公司 |
靶向cd19的人源化嵌合抗原受体制备及其应用
|
|
CA3184940A1
(en)
|
2020-07-07 |
2022-01-13 |
Jennifer Donglan WU |
Mic antibodies and binding agents and methods of using the same
|
|
US20230310606A1
(en)
|
2020-07-17 |
2023-10-05 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
US20220031751A1
(en)
|
2020-08-03 |
2022-02-03 |
Kyverna Therapeutics, Inc. |
Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
|
EP4196504A1
(en)
|
2020-08-13 |
2023-06-21 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Igg4 hinge-containing chimeric antigen receptors targeting glypican-1 (gpc1) for treating solid tumors
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
|
CN114438034A
(zh)
*
|
2020-11-06 |
2022-05-06 |
上海赛比曼生物科技有限公司 |
一种基因修饰的细胞制备方法
|
|
CN116635062A
(zh)
|
2020-11-13 |
2023-08-22 |
诺华股份有限公司 |
使用表达嵌合抗原受体(car)的细胞的组合疗法
|
|
US20230406922A1
(en)
*
|
2020-11-20 |
2023-12-21 |
Simcere Zaiming Pharmaceutical Co., Ltd. |
Humanized cd19 antibody and use thereof
|
|
WO2022111562A1
(zh)
*
|
2020-11-26 |
2022-06-02 |
上海医药集团生物治疗技术有限公司 |
一种经修饰的免疫细胞及其应用
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
CA3201621A1
(en)
|
2020-12-03 |
2022-06-09 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
US11883432B2
(en)
|
2020-12-18 |
2024-01-30 |
Century Therapeutics, Inc. |
Chimeric antigen receptor system with adaptable receptor specificity
|
|
TW202242117A
(zh)
|
2020-12-30 |
2022-11-01 |
美商亞勞諾斯醫療公司 |
包含多順反子表現卡匣之重組載體及其使用方法
|
|
JP2024503027A
(ja)
|
2021-01-11 |
2024-01-24 |
サナ バイオテクノロジー,インコーポレイテッド |
Cd8標的ウイルスベクターの使用方法
|
|
US20240425563A1
(en)
*
|
2021-01-13 |
2024-12-26 |
Washington University |
MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
|
|
CN117062611A
(zh)
|
2021-01-26 |
2023-11-14 |
惠和生物技术(上海)有限公司 |
嵌合抗原受体(car)构建体和表达car构建体的nk细胞
|
|
WO2022165419A1
(en)
|
2021-02-01 |
2022-08-04 |
Kyverna Therapeutics, Inc. |
Methods for increasing t-cell function
|
|
WO2022180586A1
(en)
*
|
2021-02-25 |
2022-09-01 |
Senthil Natesan |
Car t-cell product and method of preparation thereof
|
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
|
JP2024514245A
(ja)
|
2021-03-29 |
2024-03-29 |
ジュノー セラピューティクス インコーポレイテッド |
チェックポイント阻害剤療法とcar t細胞療法との組合せを用いた投薬および処置のための方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
JP2024514163A
(ja)
|
2021-04-16 |
2024-03-28 |
セルジーン コーポレーション |
Bcma指向性t細胞療法を用いた併用療法
|
|
CN117529333A
(zh)
|
2021-04-16 |
2024-02-06 |
细胞基因公司 |
对先前进行过干细胞移植的患者的t细胞疗法
|
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
|
WO2022234158A1
(es)
*
|
2021-05-06 |
2022-11-10 |
Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) |
Terapia de células t con receptor de antígeno quimérico específico de cd19
|
|
KR20240018454A
(ko)
|
2021-05-06 |
2024-02-13 |
주노 테라퓨틱스 게엠베하 |
T 세포의 자극 및 형질도입 방법
|
|
US20250304915A1
(en)
|
2021-05-25 |
2025-10-02 |
Institut Curie |
Myeloid Cells Overexpressing BCL2
|
|
AU2022288058A1
(en)
|
2021-06-07 |
2023-11-16 |
Agonox, Inc. |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
CA3222770A1
(en)
|
2021-06-15 |
2022-12-22 |
Takeda Pharmaceutical Company Limited |
Method for producing natural killer cells from pluripotent stem cells
|
|
CN113462646B
(zh)
*
|
2021-06-30 |
2022-06-24 |
徐州医科大学 |
一种简单有效的诱导扩增iNKT细胞的方法及应用
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
WO2023019128A1
(en)
*
|
2021-08-09 |
2023-02-16 |
The Trustees Of The University Of Pennyslvania |
Optimizing t cell differentiation state with micrornas
|
|
TW202323521A
(zh)
|
2021-08-20 |
2023-06-16 |
瑞士商諾華公司 |
製備表現嵌合抗原受體的細胞之方法
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、b細胞成熟抗原に特異的なキメラ抗原受容体
|
|
JP2024540360A
(ja)
|
2021-11-09 |
2024-10-31 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
グリピカン-3(GPC3)を標的にするIgG4ヒンジ含有キメラ抗原受容体およびその使用
|
|
US20240408192A1
(en)
|
2021-12-17 |
2024-12-12 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
US20250144214A1
(en)
|
2022-02-15 |
2025-05-08 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
|
|
EP4479143A1
(en)
|
2022-02-18 |
2024-12-25 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2023208157A1
(zh)
*
|
2022-04-29 |
2023-11-02 |
上海先博生物科技有限公司 |
靶向cd19的嵌合抗原受体及其应用
|
|
WO2023215738A1
(en)
|
2022-05-02 |
2023-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions targeting gpc2 and gpc3 and their use for treating solid tumors
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
EP4522183A2
(en)
|
2022-05-11 |
2025-03-19 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023237663A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
|
|
EP4543923A1
(en)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
JP2025523107A
(ja)
*
|
2022-07-15 |
2025-07-17 |
アルバート アインシュタイン カレッジ オブ メディスン |
Tmigd2共刺激ドメインを含むキメラ抗原受容体及びその使用方法
|
|
EP4580658A1
(en)
|
2022-08-31 |
2025-07-09 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
KR20250067174A
(ko)
|
2022-09-15 |
2025-05-14 |
노파르티스 아게 |
키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
|
|
EP4598565A1
(en)
|
2022-10-07 |
2025-08-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
AU2023365081A1
(en)
*
|
2022-10-18 |
2025-05-01 |
Kite Pharma, Inc. |
Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
CN116063575A
(zh)
*
|
2022-11-15 |
2023-05-05 |
北京瑜阳科技有限公司 |
一种嵌合抗原受体(car)以及在治疗肿瘤中的应用
|
|
KR20250121074A
(ko)
|
2022-12-09 |
2025-08-11 |
주노 쎄러퓨티크스 인코퍼레이티드 |
홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
|
|
WO2024133052A1
(en)
*
|
2022-12-19 |
2024-06-27 |
Universität Basel Vizerektorat Forschung |
T-cell receptor fusion protein
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
CN120641113A
(zh)
|
2023-03-31 |
2025-09-12 |
西比曼生物科技集团 |
靶向cd20和bcma的双特异性嵌合抗原受体
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
AU2024264056A1
(en)
|
2023-04-28 |
2025-11-20 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Modified delivery vector and use thereof
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
WO2024251263A1
(en)
|
2023-06-09 |
2024-12-12 |
Jw Therapeutics R & D (Shanghai) Co., Ltd. |
Fusion protein and medical use thereof
|
|
WO2025051339A1
(en)
|
2023-09-05 |
2025-03-13 |
Tiber Biotech Srl |
SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025072450A1
(en)
|
2023-09-26 |
2025-04-03 |
Werewolf Therapeutics, Inc. |
Enhanced adoptive cell therapy
|
|
WO2025125363A1
(en)
|
2023-12-11 |
2025-06-19 |
Institut National de la Santé et de la Recherche Médicale |
Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
|
|
EP4574838A1
(en)
|
2023-12-21 |
2025-06-25 |
Vilnius University |
Chimeric antigen receptor (car) with enhanced recruitment of signaling partners
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025191300A1
(en)
|
2024-03-12 |
2025-09-18 |
Novartis Ag |
Rapcabtagene autoleucel for use in treating systemic lupus erythematosus
|
|
WO2025219870A1
(en)
*
|
2024-04-15 |
2025-10-23 |
Biocell Innovations Pte Ltd |
Modified cd19-targeted chimeric antigen receptor (car)-t cell and uses thereof
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|
|
WO2025242732A1
(en)
|
2024-05-21 |
2025-11-27 |
Institut National de la Santé et de la Recherche Médicale |
Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
|
|
WO2025245381A1
(en)
|
2024-05-23 |
2025-11-27 |
The Trustrees Of Dartmouth College |
Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
|